For research use only. Not for human or veterinary use. 21+.
Buy one, get one freeOn every vial · no code neededShop the offer
MANUFACTURED & SHIPPED FROM THE USA
Tesamorelin + Ipamorelin 12 / 2 mg — Peptides Only, research use only
Blends · GH Axis

Tesamorelin + Ipamorelin

Third-party tested · COA with every order

GHRH analogue and selective secretagogue in a single vial.

  • Independently tested
  • Lot-matched COA
  • Lyophilized for stability
  • Ships from the USA
Research use only. Not for human or veterinary use. Sold to qualified researchers aged 21+.
$175.002 for $175 — $87.50 per vial
Buy one, get one free. Mix and match any 2 eligible vials and the lower-priced one is free — applied automatically. One-time purchases only.
1
Tesamorelin + Ipamorelin$175.002 for $175
Lot-matched documentation. Every order ships with the certificate for its lot. If a vial arrives damaged or doesn't match its paperwork, tell us within 72 hours and we'll replace it.

Latest lab results

Third-party tested

The certificate for the current lot is being uploaded. Every order ships with the COA for its lot, or request it now.

About Tesamorelin + Ipamorelin

GHRH analogue and selective secretagogue in a single vial.

Supplied as

12 / 2 mg per vial, as a lyophilized powder in a sealed glass vial with a crimped cap. The lot number on the label matches the certificate of analysis in the COA library.

Storage and handling

Store lyophilized powder frozen (−20 °C) or refrigerated, sealed and away from light. Once reconstituted, keep refrigerated (2–8 °C).

Handle in a laboratory setting using appropriate protective equipment. Consult the certificate of analysis and safety data for lot-specific information.

Important research notice. This product is intended solely for in-vitro and laboratory research. It is not a drug, food, supplement or cosmetic, has not been evaluated by the FDA, and must not be used in humans or animals. Peptides Only does not provide usage or dosing information.

Research summary

Tesamorelin + Ipamorelin is a research blend that pairs tesamorelin, a stabilized growth hormone-releasing hormone (GHRH) analog, with ipamorelin, a selective ghrelin-receptor agonist, in one lyophilized vial. The two peptides drive pituitary growth hormone (GH) release through different receptors, which is why GH-axis researchers study the classes together; no published study has tested this exact blend.

Also known as
Tesamorelin/Ipamorelin blend · Tesamorelin and Ipamorelin

What is in the vial?

Each vial holds 12 mg of tesamorelin and 2 mg of ipamorelin, lyophilized together. Tesamorelin is the 44-residue human GHRH sequence with an N-terminal trans-3-hexenoyl group that resists dipeptidyl aminopeptidase-IV breakdown1. Ipamorelin is the pentapeptide Aib-His-D-2-Nal-D-Phe-Lys-NH22. Both are also sold individually as tesamorelin and ipamorelin.

Because the vial contains two peptides of very different size, identity testing should confirm both. Every Peptides Only lot ships with a lot-matched certificate of analysis (HPLC purity and mass-spec identity) from an independent lab, published in the COA library.

Why are tesamorelin and ipamorelin studied together?

GH secretion has two stimulatory inputs. GHRH acts through its own receptor, while synthetic GH secretagogues act through a separate G protein-coupled receptor in the pituitary and hypothalamus, GHS-R, cloned in 19963; its natural ligand, the stomach peptide ghrelin, was identified in 19994. In healthy men, a GH-releasing peptide given together with GHRH released GH synergistically, and the authors concluded that the two act independently5.

That synergy is the rationale for pairing a GHRH analog with a ghrelin-receptor agonist. Ipamorelin is a logical partner because, in swine, it released GH without significant rises in ACTH or cortisol, a selectivity its developers likened to GHRH itself2.

The research behind each component

  • Tesamorelin: in a 412-participant phase 3 trial in people with HIV and abdominal fat accumulation, visceral adipose tissue fell 15.2% with tesamorelin versus a 5.0% rise with placebo, and IGF-1 rose 81%6. Tesamorelin is the active ingredient of an FDA-approved medicine for excess abdominal fat in HIV-associated lipodystrophy; this research blend is not that medicine.
  • Ipamorelin: characterized in rat pituitary cells, anesthetized rats and conscious swine, where its GH-releasing potency and efficacy were similar to GHRP-6 and antagonist studies placed its action at the GHRP (ghrelin) receptor2. It has never been approved as a medicine.

What is not known

No published study has examined tesamorelin and ipamorelin together, at this ratio or any other, so the case for combining them rests on earlier work with other GH-releasing peptides and native GHRH5. How the two behave together in a given model, and their stability when stored as a combined lyophilizate, are questions for the researcher. For the wider picture, see Ipamorelin vs Sermorelin vs Tesamorelin.

Tesamorelin + Ipamorelin FAQ

Has the tesamorelin and ipamorelin blend been studied?

Not as a blend. Each component has its own literature2,6, and synergy between GHRH and a GH-releasing peptide has been shown with other molecules5, but no published study tests this combination.

What is the difference between tesamorelin and ipamorelin?

Tesamorelin is a 44-residue GHRH analog1; ipamorelin is a five-residue agonist of the ghrelin receptor (GHS-R)2,3. They belong to different classes that converge on pituitary GH release.

How does this differ from CJC-1295 + Ipamorelin?

Both blends pair a GHRH-receptor agonist with ipamorelin. Here the GHRH component is tesamorelin, the analog with phase 3 clinical data6; the CJC-1295 + Ipamorelin blend uses CJC-1295 instead. Neither blend has been studied as such.

Is the tesamorelin and ipamorelin blend FDA-approved?

No. Tesamorelin alone is the active ingredient of an FDA-approved medicine; this blend is a research reagent that is not approved for any human use, and ipamorelin has never been approved as a medicine.

Further reading

References

  1. Ferdinandi ES, Brazeau P, et al. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. 2007;100(1):49-58. PubMed 17214611
  2. Raun K, Hansen BS, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-61. PubMed 9849822
  3. Howard AD, Feighner SD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-7. PubMed 8688086
  4. Kojima M, Hosoda H, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-60. PubMed 10604470
  5. Bowers CY, Reynolds GA, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab. 1990;70(4):975-82. PubMed 2108187
  6. Falutz J, Allas S, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-70. PubMed 18057338

Research summary reviewed 2026-10-26 against the cited literature.

More Blends

You might also need

View all
GLOW Blend 70 mg — Peptides Only, research use onlyBuy One Get One
Lyophilized vial

GLOW Blend

GHK-Cu, BPC-157 and TB-500 blended for skin-matrix research.

$200.00
2 for $200 · $100/vial

Contact Peptides Only

Operated by DND Wellness LLC · 1309 Coffeen Ave, Suite 1200, Sheridan, WY 82801.

support@peptides-only.com · (508) 404-8124

Use the chat widget to ask a question. Informational and promotional text messages require separate, optional consent. Message frequency varies. Msg & data rates may apply. Reply STOP to unsubscribe or HELP for help. Consent is not a condition of purchase. 21+.

SMS consent & support · SMS terms & Terms of Service · Privacy Policy